Am I missing something here?
To me, in laymans tems, PAR have realised that this stuff not only works, it works for extended duration.
Hence the introduction of the additional follow-up period to measure the duration of effect.
Hence:
• An additional follow-up period to 12-months has also been accepted by the ethicscommittee to assist Paradigm gather additional data on the medium-long termcombined structure-modifying and symptom-modifying effects of PPS on Knee OA(KOA).
• The additional follow-up period to 12 months and the disease modifying synovialfluid biomarkers are important to the Company to support maximum reimbursementprice for Zilosul® once registered. $$$
Clearly results to date a promising and deliving positive results.
When you go to market you need to know how long this will last for and it will have a considerable impact to valuation.
I think this is positive news.
I also think it will not impact the FDA response due back within days.
Yes, it's a slighly slower burn now, but wow, strap in...
- Forums
- ASX - By Stock
- Ann: Phase 2 Synovial Fluid Biomarker Study Update
Am I missing something here?To me, in laymans tems, PAR have...
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
26.0¢ |
Change
0.010(4.00%) |
Mkt cap ! $91.06M |
Open | High | Low | Value | Volume |
25.0¢ | 26.0¢ | 25.0¢ | $36.40K | 143.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 40816 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 44646 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 40816 | 0.245 |
3 | 50491 | 0.240 |
6 | 123811 | 0.235 |
8 | 113649 | 0.230 |
8 | 120467 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 44646 | 4 |
0.265 | 96349 | 5 |
0.270 | 40288 | 5 |
0.275 | 13636 | 2 |
0.280 | 111247 | 8 |
Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |